Swedish DPI developer Iconovo has announced that it will lay off about 10 employees as it switches its focus to commercialization of its existing dry powder inhalation platforms, including the ICOres reservoir-based DPI, the ICOpre generic version of Ellipta, and the ICOone single use device in both inhaled and nasal versions. Instead of continuing to do all … [Read more...] about Iconovo announces it will downsize and focus on commercialization of existing DPI platforms
Products and Services
Nanopharm announces clinical study to validate SmartTrack platform for demonstration of BE for inhaled drug products
AptarGroup announced that its subsidiary Nanopharm is initiating a clinical study to validate the SmartTrack in-vitro-in-silico modeling platform as an alternative to clinical endpoint studies for determining bioequivalence of inhaled drug products. The study will also collect PK data for validation of Nanopharm's Simhalation physically-based pharmacokinetic (PBPK) … [Read more...] about Nanopharm announces clinical study to validate SmartTrack platform for demonstration of BE for inhaled drug products
Iconovo gets new European patent covering its ICOres inhaler platform
According to Iconovo, the European Patent Office has indicated that it will approve a patent application for an additional patent that will provide protection for Iconovo's ICOres reservoir-based dry powder inhaler platform until 2038. ICOres is already covered by patents in a number of countries, including Japan, China, and the US. Iconovo CEO Johan Wäborg … [Read more...] about Iconovo gets new European patent covering its ICOres inhaler platform
Aerogen opens India headquarters
Irish nebulization specialist Aerogen has announced the official opening of its India headquarters in New Delhi. According to Aerogen, the New Delhi office includes a library and recreation space in addition to offices for sales, marketing, and clinical personnel. The company said that it expects to expand staff at the location from 14 employees to 30 within 5 years … [Read more...] about Aerogen opens India headquarters
Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell
Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR study of CYR-064 that was initiated in 2023 has been using an Ursatec spray pump enhanced with the Resyca technology for … [Read more...] about Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell
Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development of "a comprehensive plan for the scale-up of foralumab in a nasal device." Tiziana is … [Read more...] about Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab
Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices
Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch of its ZEOx1 OrionMRQ multi-dose nasal device for delivery of liquid drugs and vaccines. According to Zeteo, the new dry powder nasal … [Read more...] about Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices
Inhalon announces plans for Phase 2a challenge study of IN-002 inhaled antibody against RSV
Inhalon Biopharma announced that it has contracted with hVIVO to conduct a Phase 2a challenge study of nebulized IN-002, an antibody against RSV, now that Inhalon has completed IND-enabling studies. The company said that it expects to initiate the trial of IN-002 in 2026. Inhalon's pipeline of inhaled antibodies also includes IN-003 against metapneumovirus, IN-005 … [Read more...] about Inhalon announces plans for Phase 2a challenge study of IN-002 inhaled antibody against RSV
Kenox Pharmaceuticals adds small scale GMP capability for OINDPs
OINDP specialist contract developer Kenox Pharmaceuticals announced that it has added a clean room for small scale manufacturing of non-sterile nasal sprays and dry powders for use in pre-clinical development. The company, which is located in Princeton, NJ, USA, said that it is also in the process of adding Phase 1 and 2 clinical scale GMP manufacturing capabilities … [Read more...] about Kenox Pharmaceuticals adds small scale GMP capability for OINDPs
Copley Scientific introduces new Powder Testing Workstation PTW and Powder Testing Assistant PTA 100i
OINDP testing specialists Copley Scientific have announced the launch of the new Powder Testing Workstation PTW for flowability testing as well as the Powder Testing Assistant PTA 100i. The customizable PTW system allows the user to select various modules for angle of repose, flow through an orifice, and bulk density testing of dry powders. The PTA 100i offers … [Read more...] about Copley Scientific introduces new Powder Testing Workstation PTW and Powder Testing Assistant PTA 100i